PremiumThe FlyOpthea downgraded to Market Perform from Outperform at Leerink Opthea cut to Market Perform at Leerink on failed sozinibercept trial Opthea double downgraded to Underperform from Buy at Jefferies PremiumRatingsOpthea Limited: Hold Rating Amid Phase 3 Trial Failure and Financial Uncertainty Opthea COAST trial misses primary endpoint, enters talks with DFA Investors Opthea Limited Suspends Trading Pending Clinical Trial Results PremiumCompany AnnouncementsOpthea Limited Announces Quotation of New Securities on ASX Opthea Limited Announces New Securities Quotation on ASX Opthea Limited Announces New Securities Quotation on ASX